A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

Breelyn A. Wilky(University of Colorado Cancer Center), Nilofer S. Azad(Johns Hopkins Hospital)

British Journal of Cancer

September 30, 2014

10.1038/bjc.2014.515

Cited by 37

Related Papers

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

|New England Journal of Medicine|2015|9.4k

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

|Science|2017|6.6k

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

|Science Translational Medicine|2014|5.1k

A Phase I Study of Veliparib (ABT-888) in Combination with Low-Dose Fractionated Whole Abdominal Radiation Therapy in Patients with Advanced Solid Malignancies and Peritoneal Carcinomatosis

|Clinical Cancer Research|2014|75

A phase 1 trial of the oral DNA methyltransferase inhibitor CC‐486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors

|Cancer|2019|56